Multi-institutional, prospective, randomized, double-blind, placebo-controlled phase IIb trial of the tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine to prevent recurrence in high-risk melanoma patients: A subgroup analysis
Robert C. Chick, Mark B. Faries, Diane F. Hale, Phillip M. Kemp Bohan, Annelies T. Hickerson, Timothy J. Vreeland, John W. Myers, Jessica L. Cindass, Tommy A. Brown, John Hyngstrom, Adam C. Berger, James W. Jakub, Jeffrey J. Sussman, Montaser Shaheen, Guy T. Clifton, Hyohyun Park, Amanda J. Sloan, Thomas Wagner, George E. Peoples
Research output: Contribution to journal › Article › peer-review
Dive into the research topics of 'Multi-institutional, prospective, randomized, double-blind, placebo-controlled phase IIb trial of the tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine to prevent recurrence in high-risk melanoma patients: A subgroup analysis'. Together they form a unique fingerprint.